Get the Stockscreener App
4.0977
0.74%
0.0377
Shattuck Labs Inc stock is traded at $4.0977, with a volume of 247.05K.
It is up +0.74% in the last 24 hours and up +22.09% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$4.06
Open:
$4.06
24h Volume:
247.05K
Relative Volume:
0.55
Market Cap:
$259.45M
Revenue:
$2.72M
Net Income/Loss:
$-85.08M
P/E Ratio:
-2.1232
EPS:
-1.93
Net Cash Flow:
$-70.93M
1W Performance:
-5.76%
1M Performance:
+22.09%
6M Performance:
+383.34%
1Y Performance:
+258.77%
1-Day Range:
$3.94
$4.135
1-Week Range:
$3.94
$4.65
52-Week Range:
$0.6922
$4.89
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
4.10 | 256.92M | 2.72M | -85.08M | -70.93M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.10 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.45 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.09 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.12 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Will DAKT stock hit new highs in YEAR2025 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Shattuck Labs Launches $75 Million At-The-Market Offering - TipRanks
Shattuck Labs Inc enters $75 million common stock sales agreement with Leerink Partners - marketscreener.com
Earnings Risk: Why is Shattuck Labs Inc stock going downJuly 2025 Setups & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is Shattuck Labs Inc.’s growth already priced inJuly 2025 Setups & Growth Oriented Trade Recommendations - bollywoodhelpline.com
Resistance Check: Is Shattuck Labs Inc stock a value trapQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Update - Defense World
Shattuck Labs: "Hold" On Oncology Exit And Competitive TL1A/DR3 Pathway Pivot (STTK) - Seeking Alpha
Shattuck Labs (STTK) Price Target Increased by 16.67% to 4.76 - Nasdaq
Shattuck Labs Files $200 Million Mixed Shelf - marketscreener.com
Pullback Watch: Why is Comtech Telecommunications Corp stock going upWeekly Trading Summary & Community Consensus Trade Alerts - baoquankhu1.vn
CEO Change: How Shattuck Labs Inc stock reacts to Fed rate cuts2025 Risk Factors & Long Hold Capital Preservation Plans - Bộ Nội Vụ
Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
How interest rate cuts could boost Shattuck Labs Inc. stockEarnings Performance Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Will Shattuck Labs Inc. stock gain from lower inflationLong Run Comfort Guide & lightweight options for faster days - Улправда
How Shattuck Labs Inc. stock reacts to global recession fearsJuly 2025 Final Week & AI Enhanced Execution Alerts - Улправда
Can Shattuck Labs Inc. stock attract ESG capital inflowsWeekly Gains Report & Stepwise Entry and Exit Trade Signals - Улправда
Is Shattuck Labs Inc. stock a top pick in earnings seasonBull Run & Weekly Stock Breakout Alerts - Улправда
Individual Investors Are Shattuck Labs, Inc.'s (NASDAQ:STTK) Biggest Owners and Were Rewarded After Market Cap Rose by US$73m Last Week - 富途牛牛
Shattuck Labs (NASDAQ:STTK) Trading 20.6% HigherTime to Buy? - MarketBeat
Shattuck Labs (NASDAQ:STTK) Trading 20.6% Higher – Time to Buy? - Defense World
Does Shattuck Labs Inc. stock trade at a discount to peersRisk Adjusted Returns & You’ve Never Seen Stock Picks Like These - Улправда
Why Shattuck Labs stock soared in December - MSN
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - AOL.com
Shattuck Labs (STTK): Citigroup Maintains Neutral Rating, Raises Price Target | STTK Stock News - GuruFocus
Shattuck Labs (STTK) Stock Soars 74% Following Analyst Upgrade to Buy - Intellectia AI
Why Shattuck Labs Stock Soared in December - Yahoo Finance
Several Insiders Invested In Shattuck Labs Flagging Positive News - Yahoo Finance
Shattuck Labs (STTK) Price Target Increased by 15.61% to 2.72 - MSN
Shattuck Labs, Inc.'s (NASDAQ:STTK) biggest owners are retail investors who got richer after stock soared 10% last week - simplywall.st
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - AOL.com
Shattuck Labs Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Why Shattuck Labs Inc. stock is a must watch in 2025Portfolio Update Report & Daily Volume Surge Trade Alerts - Улправда
How Shattuck Labs Inc. stock performs in rate cut cyclesMarket Activity Recap & Daily Profit Maximizing Trade Tips - Улправда
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Shattuck Labs (NASDAQ:STTK) Shares Down 1.3%Time to Sell? - MarketBeat
Shattuck Labs (NASDAQ:STTK) Shares Down 1.3% – Time to Sell? - Defense World
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Shattuck Labs announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Shattuck Labs (NASDAQ: STTK) grants 206K inducement options under Rule 5635(c)(4) - Stock Titan
A History of Outperforming Analyst Forecasts and Beating the Odds: Shattuck Labs Inc (STTK) - setenews.com
Shattuck Labs (STTK) price target increased by 33.33% to 4.08 - MSN
Shattuck Labs (STTK) Price Target Increased by 33.33% to 4.08 - Nasdaq
What's Next For Shattuck Labs? SL-325 And Bispecific Antibody Programs - RTTNews
Why Shattuck Labs Inc. stock remains undervalued2025 Dividend Review & Weekly Top Performers Watchlists - Newser
STTK: Receptor-targeted TL1A therapy shows promise for safer, more effective treatment and rapid development - TradingView
Shattuck Labs, Inc. (STTK) Slides 8% in Pre-market: Without a Clear Catalyst - Stocks Telegraph
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ashiya Mona | Director |
Aug 25 '25 |
Buy |
0.87 |
6,306,127 |
5,471,826 |
5,255,106 |
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):